Featured Videos

The future of antibody claiming in the United States is uncertain following the U.S. Supreme Court’s ruling in ‘Amgen Inc. v. Sanofi,’ a highly anticipated decision concerning enablement and whether the traditional way to claim antibodies — claiming antibodies by their function — will survive as a valid claiming strategy.        

John Quinn, co-founder of one of the world’s leading litigation firms, talks about global litigation opportunities, the rise of class actions in Europe and podcasting about the law.        

John Roesser told Judge Analisa Torres that he has “always, always, always loved the law” and regretted the impact of his offense on the court system.        

In part, Meridian argued that the Batstones miscalculated the prejudgment interest by calculating them from the date of the defendants’ original denial. The judge agreed.